Personalized Chemoradiation for Lung Cancer
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research suggests that personalized radiotherapy, which tailors treatment to the specific characteristics of a patient's tumor, can improve outcomes in lung cancer. Additionally, tools like the Radiotherapy Outcomes Estimator help optimize radiotherapy prescriptions, potentially enhancing the effectiveness of treatments like Model Based Personalized Chemoradiation.
12345The research on similar treatments, like chemoradiotherapy combined with other drugs, shows that they generally have a manageable safety profile, but the specific safety of Personalized Chemoradiation for Lung Cancer would need to be confirmed in its own studies.
46789This treatment is unique because it combines personalized chemotherapy and radiation therapy, potentially using Tecentriq (an immunotherapy drug) to enhance the effectiveness of radiation by targeting specific molecular pathways in the tumor, which may improve outcomes for patients with hard-to-treat lung cancer.
1011121314Eligibility Criteria
Adults with locally advanced non-small cell lung cancer who can sign consent, undergo thoracic radiation and systemic therapy (like chemo), and perform cardiac tests. They must have a Karnofsky performance status of 70 or above, indicating they are able to care for themselves. Excluded are those with prior chest radiation, pregnant or breastfeeding women, renal failure patients on dialysis, or anyone unable to do the required heart imaging tests.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation Therapy (RT)
Participants undergo SPECT/CT with stress test and echocardiogram with strain before RT, and participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT
Chemoradiation (CRT)
Participants receive chemoradiation treatment and undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT
Follow-up
Participants are monitored for safety and effectiveness after treatment, including SPECT/CT with stress test and echocardiogram with strain, 6 MWT, and blood sample collection at 6-8 weeks, 4-6 months, 12 months, and annually up to 10 years
Participant Groups
Model Based Personalized Chemoradiation is already approved in European Union, United States for the following indications:
- Urothelial carcinoma
- Non-small cell lung cancer
- Small cell lung cancer
- Hepatocellular carcinoma
- Alveolar soft part sarcoma
- Non-small cell lung cancer
- Small cell lung cancer
- Hepatocellular carcinoma
- Melanoma
- Alveolar soft part sarcoma